title: [Systemic treatments for psoriasis and psoriatic arthritis].
abstract: Psoriasis is one of the most common chronic dermatoses. More than 25 % of the affected individuals require effective systemic treatment because of severe symptoms and/or the significantly restricted quality of life. Thanks to intensive research and successful cooperation between academia and the pharmaceutical industry, the options for treating psoriasis have dramatically increased in recent years. Especially targeted therapies give us the opportunity for personalized regimen. This review describes the spectrum of the systemic treatments for psoriasis and psoriatic arthritis and discusses the efficacy, safety, and particular features of the individual substances.
authors.affiliation: Psoriasis Forschungs- und Behandlungs-Centrum, Klinik für Dermatologie, Venerologie und Allergologie und Institut für Medizinische Immunologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.
authors.forename: S
authors.initials: S
authors.lastname: Philipp
authors.affiliation: Psoriasis Forschungs- und Behandlungs-Centrum, Klinik für Dermatologie, Venerologie und Allergologie und Institut für Medizinische Immunologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.
authors.forename: G
authors.initials: G
authors.lastname: Kokolakis
authors.affiliation: Psoriasis Forschungs- und Behandlungs-Centrum, Klinik für Dermatologie, Venerologie und Allergologie und Institut für Medizinische Immunologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland. robert.sabat@charite.de.|Interdisziplinäre Gruppe Molekulare Immunpathologie, Dermatologie/Med. Immunologie, Charité - Universitätsmedizin Berlin, Berlin, Deutschland. robert.sabat@charite.de.
authors.forename: R
authors.initials: R
authors.lastname: Sabat
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D003879:Dermatologic Agents / Q000008:administration & dosage*; D019317:Evidence-Based Medicine; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D058990:Molecular Targeted Therapy / Q000379:methods*; D011565:Psoriasis / Q000175:diagnosis / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents
keywords: Biologics; Biosimilars; IL-17; Small molecules; TNF